RenaudBonnet

Practice Leader Private Equity

巴黎 + 33.1.56.59.39.14

聯絡

*Share

Renaud Bonnet is co-leader of Private Equity for the Firm's Corporate Practice. His practice areas include venture capital, private equity, M&A, and capital markets. He represents technology and life sciences companies, as well as the private equity and industrial investors that finance them, at every stage of development from entrepreneurial start-ups to multibillion dollar global corporations. He has acted as principal lawyer in a significant number of early to late-stage financing rounds, LBO and other M&A transactions, joint ventures, initial public offerings, rights issues, private placements, and tender offers.

Renaud's recent experience includes representations of technology and life sciences companies Adocia, Ansys, Cellectis, Criteo, Deezer, Devialet, EcoVadis, HRA Pharma, Ivalua, 360Learning, ManoMano, Nanobiotix, Planisware, Prodways, Sigfox, Talend, and Voltalia. His recent investor-side representations include: Abingworth, Alven, Bain Capital Ventures, Bpifrance, Creadev, Danone Ventures, Elaia, Felix Capital, Goldman Sachs, Orange, Hi Inov, Idinvest, Institut Pasteur, Sanofi, Seventure, Sofinnova, and Temasek.

Transactions in which Renaud acted as lead lawyer include: representing the issuer and/or underwriters in more than 100 IPOs and follow-on offerings; the IPOs of Criteo, Cellectis, Nanobiotix, and Talend on Nasdaq; the tender offers on Completel, Wavecom, Assystem, and TxCell; the LBOs of HRA Pharma by Astorg and Goldman Sachs, Orolia by Eurazeo, A2Mac1 by Five Arrows, and Brico Privé by Florac; the sale of Novexel to AstraZeneca and Synthesio to Ipsos; the acquisition of French technology companies by Autodesk, Criteo, SAP, and Ansys; and the latest financing rounds of Devialet, Ivalua, ManoMano, and EcoVadis.

Renaud was a member of the Consultative Commission on Issuers' Transactions and Financial Information of the French Financial Markets Authority (AMF) from 2017 to 2019.

執業經驗

  • Elaia Partners participates in £35 million Series B financing of DocclaJones Day advised Elaia Partners in connection with its participation in the £35 million Series B financing of Doccla, the leading provider of virtual ward and remote patient monitoring services, particularly targeting France and the DACH region for expansion while also positioning the company for potential growth in other international markets beyond Europe.
  • Silicon Mobility sold to IntelJones Day advised Silicon Mobility SAS in the acquisition of the company by Intel Corporation.
  • Cellectis and AstraZeneca enter into research collaboration and agree on equity investment of up to $220 million by AstraZenecaJones Day advised Cellectis in connection with the joint research collaboration agreement entered into with AstraZeneca and initial equity investment by AstraZeneca into Cellectis of $80 million.
  • TiLT Capital Partners leads €46 million financing of EODevJones Day advised TiLT Capital Partners SAS in leading the €46 million financing of EODev, along with Supernova Invest, CapHorn, Pulse (CMA-CGM), and the existing shareholders of EODev, to strengthen its leading position in the hydrogen fuel cell power generators market by financing its investment program, the expansion of its product range, and the acceleration of its commercial development.
  • Contentsquare acquires HeapJones Day acted as French counsel to Contentsquare in the acquisition of Heap, a leading U.S. product analytics platform.
  • Arverne Group combines with Transition to publicly list on Euronext Paris the future French leader in geothermal and low-carbon lithium to drive energy transitionJones Day advised Arverne Group SAS, a French company ("Arverne"), in its business combination with Euronext listed Transition SA to create the future French leader in geothermal and low-carbon lithium production.
  • Sofinnova and NVentures co-lead $55.4 million financing of Moon SurgicalJones Day advised Sofinnova Partners (through Sofinnova Capital Strategy) and NVentures (NVIDIA's venture capital arm) as lead investors in connection with the $55.4 million financing of Moon Surgical, a French-American pioneer in collaborative robotics.
  • CVE raises €100 million from ICG InfraJones Day advised CVE, a France-based independent producer of renewable energy across multiple countries and sources of power, in connection with its €100 million financing round led by Intermediate Capital Group plc, a global alternative asset manager, through its infrastructure investment arm (ICG Infra).
  • Lithium de France raises €44 million in Series B financingJones Day advised Lithium de France, first independent French operator of geothermal heat and lithium, in connection with its €44 million Series B financing subscribed by its main shareholders, Arverne Group, Equinor Ventures AS, and a new investor Hydro Energi Invest AS.
  • Welcome to the Jungle raises €50 million in Series C financingJones Day represented Welcome to the Jungle, a company that develops and operates a recruitment and employer branding solution, in connection with its €50 million Series C financing led by Cipio Partners and Blisce alongside new investors, Kostogri, Groupe ADP, and Raise Sherpas, and existing investors, Revaia, XAnge, and Bpifrance (Digital Venture).
  • Macquarie agrees to acquire Suez Recycling and Recovery UK Group for approximately €2.4 billionJones Day advised Macquarie Asset Management in the execution of a put option agreement to acquire 100% of the shares of Suez Recycling and Recovery UK Group for €2.4 billion.
  • Content Square obtains $200 million revolving credit facilityJones Day advised Content Square, a digital experience analytics company and one of France's largest technology unicorns, in connection with a $200 million revolving credit facility provided by a syndicate of banks.
  • TiLT Capital Partners participates in €9.8 million Series A financing of Watt & WellJones Day advised Tilt Capital Partners SAS in connection with the €9.8 million Series A financing of Watt & Well, a designer and manufacturer of electronic power equipment, along with BNP Paribas Développement and Bpifrance.
  • Eurobio Scientific acquires GenDxJones Day advised Eurobio Scientific SA in the acquisition and financing of the Dutch company Genome Diagnostics BV (GenDx) from its founder and its shareholders for €135 million (net of adjusted cash).
  • Deezer invests to create livestreaming powerhouse as Driift acquires DreamstageJones Day advised Deezer S.A. in its £4 million investment in the merger of Driift and Dreamstage, creating a livestreaming powerhouse.
  • Creadev and Temasek invest in InnovafeedJones Day advised Creadev SAS and Temasek, investors in the $250 million Series D financing of Innovafeed, a leader in the production of insects (Hermetia Illucens) for animal and plant nutrition.
  • Deezer merges with and into I2PO S.A.Jones Day advised Deezer S.A. in the context of the SPAC transaction whereby Deezer S.A. merged with and into I2PO S.A., a French SPAC listed on the professional segment of the regulated market of Euronext Paris and the related PIPE financing.
  • EcoVadis completes $500 million fundraising, becoming 27th French unicornJones Day advised EcoVadis, a leading global sustainability rating firm, in connection with its $500 million fundraising.
  • Therapixel raises €15 million in Series B financing roundJones Day advised Therapixel, a designer and supplier of MammoScreen® an Artificial Intelligence software reading aid for mammography, in the €15 million Series B round of financing led by Crédit Mutuel Innovation and CapHorn.
  • Hi Inov, Omnes, and Swen Capital Partners invest in SkillupJones Day represented Hi Inov, Omnes, and Swen Capital Partners in connection with the €8 million round of financing along with existing investors Global Founders Capital and Kerala in Skillup, a human resource talent management SaaS.
    •

    March 2023 White Paper

    2022 Annual M&A/PE Review and 2023 Forecast

    December 2022 Webinars

    Webinar Series: Cross-Practice Issues in the Life Sciences

    January 2022 White Paper

    2021 Transactional Year in Review and 2022 Forecast

    January 2022 White Paper

    FDI Regimes Continue to Expand and Increase Scrutiny of Transactions Worldwide

    February 2021 White Paper

    2020 Transactions Year in Review

    June 2016 Alert

    Brexit: United Kingdom Votes to Leave the EU

    September 18-20, 2023 Speaking Engagements

    Jones Day lawyers to attend IPEM 2023

    December 2022 Webinars

    Webinar Series: Cross-Practice Issues in the Life Sciences

    • 29 janvier 2014
      Le private equity en 2014 : tendances et opportunités
    • 29 janvier 2013
      Le Private Equity : où en sommes-nous ?
    • 20 septembre 2012
      Le financement des PME: actualités juridiques et tendances de marché - en partenariat avec NYSE Euronext et Société Générale
    • September 20, 2012
      SME Financing: legal news and market trends – in collaboration with NYSE Euronext and Société Générale
    • 5 avril 2011
      Atelier « Fusions & Acquisitions » de France Biotech - Le point de vue de l'avocat, intervention de Renaud Bonnet
    • 17 juin 2009
      Introductions en bourse : la mission de l’avocat conseil et la problématique règlementaire, Conférence “Penser à votre introduction en bourse : osé ... mais peut-être astucieux ! ” organisée par la Société Générale
    • 3 avril 2007
      Introductions en bourse : feuille de route pratique
    • 18 mai 2006
      Petit déjeuner thématique "Stock options, BCE, actions gratuites"
    • 14 mars 2006
      Cours à l'ESSEC, "Mécanisme d'incitation des managers"

    *Before sending, please note:

    *Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.